Testicular Cancer clinical trials

Explore recruiting testicular cancer clinical trials.

Recruiting testicular cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Testicular Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer

Sweden, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

First-in-human, open-label, multicenter, Phase I/IIa, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

Netherlands, Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Quality of Life

Finland

Therapeutic use (Phase IV) EU CTIS Study details

Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors

Sweden, Germany, Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Testicular Cancer trials by city

Testicular Cancer in Toronto Testicular Cancer in Vancouver Testicular Cancer in Montreal Testicular Cancer in Calgary Testicular Cancer in Edmonton Testicular Cancer in Ottawa Testicular Cancer in Winnipeg Testicular Cancer in Quebec City Testicular Cancer in Hamilton Testicular Cancer in Kitchener Testicular Cancer in London Testicular Cancer in Halifax Testicular Cancer in New York Testicular Cancer in Los Angeles Testicular Cancer in Chicago Testicular Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease